CTLA-4 blockade: Unveiling immune regulation

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 662-664

  Dranoff, Glenn ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FREUND ADJUVANT; GLYCOPROTEIN GP 100; IPILIMUMAB; MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; MONTANIDE ISA 51; UNCLASSIFIED DRUG; CANCER VACCINE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; DRUG DERIVATIVE; LEUKOCYTE ANTIGEN; MANNITOL; MONOCLONAL ANTIBODY; OLEIC ACID;

ABDOMINAL PAIN; ADJUVANT THERAPY; AUTOIMMUNE DISEASE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER IMMUNIZATION; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; EDITORIAL; GASTROINTESTINAL SYMPTOM; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RASH; UVEITIS; AUTOIMMUNITY; IMMUNOLOGY; NOTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; AUTOIMMUNITY; CANCER VACCINES; HUMANS; MANNITOL; MELANOMA; OLEIC ACIDS;

EID: 14144253408     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.923     Document Type: Editorial

References (18)

1. Diefenbach A, Raulet D: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188:9-21, 2002
2. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965, 1994
3. Clark W, Elder D, Guerry D, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904, 1989
4. Zhang L, Conejo-Garcia J, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213, 2003
5. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137-148, 2004
6. Coussens L, Werb Z: Inflammation and cancer. Nature 420:860-867, 2002
7. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11-22, 2004
8. Banchereau J, Steinman R: Dendritic cells and the control of immunity. Nature 392:245-252, 1998
9. Gilboa E: The promise of cancer vaccines. Nat Rev Cancer 4:401-411, 2004
10. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2:227-238, 2002
11. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225-252, 2001
12. Hori S, Takahashi T, Sakaguchi S: Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81:331-371, 2003
13. Chambers CA, Kuhns MS, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594, 2001
14. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-CTLA-4 monoclonal antibody with multiple peptides and Montanide ISA 51 for patients with resected stages III/IV melanoma J Clin Oncol 23:741-750, 2005
15. Read S, Malmstrorn V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 192:295-302, 2000
16. Ueda H, Howson JM, Esposito L, et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511, 2003
17. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
18. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717, 2003